Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OKUR vs AVTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OKUR Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 3–4 Matrix Metrics)

OKUR Overall Winner 6-Pillar Tally: OKUR 2 – 2 AVTX (2 Tie) Matrix Metrics: OKUR 3 – 4 AVTX

As of Nov 20, 2026, OnKure Therapeutics, Inc. (OKUR) is the stronger overall head-to-head candidate over Avalo Therapeutics, Inc. (AVTX) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). OKUR carries a Unified Composite Score of 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin), whereas AVTX carries 45.6/100 (HOLD) at $6.76 (N/M Forward P/E, -161962.7% operating margin).

  • Composite vs. Pillar Nuance: While AVTX currently prints a higher short-term Unified Composite Score (45.6/100 HOLD vs. OKUR 36.0/100 SELL), OKUR captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -161962.7% operating margin) and revenue trajectory (+0.0% vs. -69.3% YoY).
  • Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OKUR vs AVTX
OKUR NASDAQ Head-to-Head Winner
OnKure Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$2.70
-2.17% 1D
Market Cap $113.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 100% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 20.0 Fund 46.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.6%) with fading momentum, RSI 49
RSI-14: 48.7 · SMA20: $2.76 · SMA50: $2.67
AVTX NASDAQ
Avalo Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$6.76
+0.15% 1D
Market Cap $390.3M
TTM Revenue $59,000
Forward P/E N/M
Beta / 30D Vol 1.54β · 94% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 39.0 Fund 61.0 Flow 68.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.2%), weak momentum, RSI 33
RSI-14: 33.1 · SMA20: $7.18 · SMA50: $11.21

6-Pillar Scorecard Institutional Category Breakdown (OKUR 2 – 2 AVTX)

Columns: Metric · OKUR · AVTX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale AVTX
Revenue Growth (YoY) +0.0% -69.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $59,000
Market Cap $113.7M $390.3M
3. Profitability & Quality OKUR
Gross Margin N/A N/A
Operating Margin 0.0% -161962.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -55.2% -33.6%
4. Balance Sheet & Cash Flow OKUR
Cash Generation (TTM) -$48M -$63M
Cash Flow Margin N/A N/A
Net Cash / Leverage $151M Net Cash $65M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVTX
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 89.1% (100th %ile) 82.8% (15th %ile)
Put/Call OI Skew N/A 61.29x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Distribution DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OKUR (3) vs AVTX (4)
Institutional Metric OKUR AVTX Criterion Row Edge
Market Capitalization
Scale
$113.7M $390.3M Larger Scale AVTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -69.3% Higher Growth OKUR
Operating Margin (TTM)
Profitability
0.0% -161962.7% Higher Margin OKUR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-55.2% -33.6% Higher ROE AVTX
52-Week Range Position
Momentum
20% ($2–$5) 1% ($7–$24) Stronger Trend OKUR
Beta / 30D Volatility
Risk Regime
0.96β · 100% Vol 1.54β · 94% Vol Lower Realized Risk AVTX
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 45.6 / 100 (HOLD) Higher Composite AVTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $59,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$48M ($151M Net Cash) -$63M ($65M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OKUR +13.91 pp
OKUR: +4.65% · AVTX: -9.26%
3M Horizon OKUR +34.33 pp
OKUR: -30.59% · AVTX: -64.92%
6M Horizon OKUR +22.78 pp
OKUR: -35.87% · AVTX: -58.65%
1Y Horizon OKUR +59.4 pp
OKUR: -2.17% · AVTX: -61.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKUR vs AVTX. Trailing 12-month operating profitability (OKUR 0.0% vs AVTX -161962.7%) and valuation multiples (OKUR N/M vs AVTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OKUR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-55.2% · N/M
AVTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$59,000
Gross MarginN/A
Op. Margin-161962.7%
ROE / Fwd P/E-33.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OKUR SURGE
8d in phase · OBV DISTRIBUTION
Current IV 89.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact OKUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVTX BREAKDOWN
137d in phase · OBV DISTRIBUTION
Current IV 82.8%
IV Percentile 15th %ile
Put/Call OI Skew 61.29x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AVTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OKUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $113.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $390.3M market capitalization and -161962.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OKUR vs AVTX Key Questions & Quantitative Answers

As of Nov 20, 2026, OnKure Therapeutics, Inc. (OKUR) is the stronger overall head-to-head candidate over Avalo Therapeutics, Inc. (AVTX) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). OKUR carries a Unified Composite Score of 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin), whereas AVTX carries 45.6/100 (HOLD) at $6.76 (N/M Forward P/E, -161962.7% operating margin). Composite vs. Pillar Nuance: While AVTX currently prints a higher short-term Unified Composite Score (45.6/100 HOLD vs. OKUR 36.0/100 SELL), OKUR captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -161962.7% operating margin) and revenue trajectory (+0.0% vs. -69.3% YoY). Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVTX leads the Growth & Scale pillar: OKUR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AVTX at -69.3% YoY revenue growth and +0.0% YoY earnings growth on $59,000 TTM revenue (N/A gross margin, -161962.7% operating margin). On trailing 12-month operating scale, OKUR generates N/A in USD-normalized revenue versus $59,000 for AVTX. In operating R&D and SG&A reinvestment, OKUR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVTX.

OKUR and AVTX trade at balanced relative valuation multiples. OKUR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKUR (-55.2% ROE) versus AVTX (-33.6% ROE) capital efficiency.

In options market volatility and institutional positioning, OKUR carries 89.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 100% Vol realized risk). By comparison, AVTX carries 82.8% implied volatility (15th %ile, Compressed (<25th %ile)), a 61.29x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.54β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.